Xavier Estrany-Carbonell

Barcelona, CT 08028, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

RSV Immunoprophylaxis in Infants and Children: Old Standards, New Agents and the Complexities Therein.

RSV Immunoprophylaxis in Infants and Children: Old Standards, New Agents and the Complexities Therein.

Journal: Vaccines

Published: June 01, 2026

Meta-analysis of the efficacy of palivizumab versus nirsevimab at preventing medically attended respiratory syncytial virus infections in non-hospitalized preterm infants.

Meta-analysis of the efficacy of palivizumab versus nirsevimab at preventing medically attended respiratory syncytial virus infections in non-hospitalized preterm infants.

Journal: Human vaccines & immunotherapeutics

Published: April 01, 2026

Respiratory syncytial virus immunization in children: The old, the new and what's just around the corner.

Respiratory syncytial virus immunization in children: The old, the new and what's just around the corner.

Journal: Human vaccines & immunotherapeutics

Published: June 24, 2025

Twenty-five years of palivizumab: a global historic review of its impact on the burden of respiratory syncytial virus disease in children.

Twenty-five years of palivizumab: a global historic review of its impact on the burden of respiratory syncytial virus disease in children.

Journal: Expert review of anti-infective therapy

Published: March 20, 2025

Systematic Review and Expert Consensus on the Use of Long-acting Monoclonal Antibodies for Prevention of Respiratory Syncytial Virus Disease: ARMADA (Advancing RSV Management And Disease Awareness) Taskforce.

Systematic Review and Expert Consensus on the Use of Long-acting Monoclonal Antibodies for Prevention of Respiratory Syncytial Virus Disease: ARMADA (Advancing RSV Management And Disease Awareness) Taskforce.

Journal: Open forum infectious diseases

Published: February 19, 2025

Clinical and economic evaluation of risk factor guided respiratory syncytial virus prophylaxis in Colombian preterm infants.

Clinical and economic evaluation of risk factor guided respiratory syncytial virus prophylaxis in Colombian preterm infants.

Journal: Cost effectiveness and resource allocation : C/E

Published: February 11, 2025

Optimizing risk factors to guide COST-effective use of palivizumab in KOREAN infants.

Optimizing risk factors to guide COST-effective use of palivizumab in KOREAN infants.

Journal: Pediatrics international : official journal of the Japan Pediatric Society

Published: April 29, 2024

Opinion: The optimal use of risk factors to guide palivizumab prophylaxis against severe respiratory syncytial virus infection in moderate-to-late preterm infants.

Opinion: The optimal use of risk factors to guide palivizumab prophylaxis against severe respiratory syncytial virus infection in moderate-to-late preterm infants.

Journal: Frontiers in pediatrics

Published: November 24, 2023

A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29-35 weeks' gestational age.

A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29-35 weeks' gestational age.

Journal: PloS one

Published: May 25, 2023

Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants.

Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants.

Journal: Journal of medical economics

Published: April 17, 2023

Prioritising respiratory syncytial virus prevention in low-income and middle-income countries.

Prioritising respiratory syncytial virus prevention in low-income and middle-income countries.

Journal: The Lancet. Global health

Published: February 23, 2023

Accurately Assessing the Expected Impact of Universal First Respiratory Syncytial Virus (RSV) Season Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants.

Accurately Assessing the Expected Impact of Universal First Respiratory Syncytial Virus (RSV) Season Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants.

Journal: The Journal of infectious diseases

Published: November 12, 2022

Showing 1-12 of 42

Last Updated: 09/26/2026